Completed PHASE3 INTERVENTIONAL NCT00396175

Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia

Sponsor: Organon and Co

Conditions Androgenetic Alopecia

Interventions Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks MK0906, finasteride / Duration of Treatment : 48 Weeks

Updated 6 times since 2017 Last updated: Feb 7, 2022 Started: Mar 31, 1998 Primary completion: Jan 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Androgenetic Alopecia, this trial is completed. The trial is conducted by Organon and Co and has accumulated 6 data snapshots since 1998. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.